Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, shingles, Rabies), Route (IM, SC, ID, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2024

Table of Contents

1.... INTRODUCTION

1.1             OBJECTIVES OF THE STUDY
1.2             MARKET DEFINITION
1.3             MARKET SCOPE
1.3.1              MARKETS COVERED.. 19
1.3.2              YEARS CONSIDERED FOR THE STUDY
1.4             CURRENCY
1.5             LIMITATIONS
1.6             STAKEHOLDERS

2.... RESEARCH METHODOLOGY

2.1             RESEARCH APPROACH
2.1.1              SECONDARY RESEARCH
2.1.1.1            KEY DATA FROM SECONDARY SOURCES
2.1.2              PRIMARY RESEARCH.. 23
2.1.2.1            KEY DATA FROM PRIMARY SOURCES
2.1.2.2            BREAKDOWN OF PRIMARIES
2.2             MARKET SIZE ESTIMATION
2.3             DATA TRIANGULATION APPROACH
2.4             MARKET SHARE ANALYSIS
2.5             ASSUMPTIONS FOR THE STUDY

3.... EXECUTIVE SUMMARY

4.... PREMIUM INSIGHTS

4.1             VACCINES MARKET OVERVIEW
4.2             NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY (2018)
4.3             GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET

5.... MARKET OVERVIEW

5.1             INTRODUCTION
5.2             MARKET DYNAMICS
5.2.1              DRIVERS
5.2.1.1            HIGH PREVALENCE OF INFECTIOUS DISEASES
5.2.1.2            RISING FOCUS ON IMMUNIZATION PROGRAMS
5.2.1.3            GROWING GOVERNMENT SUPPORT FOR VACCINE DEVELOPMENT
5.2.1.4            INCREASING COMPANY INITIATIVES TO ENHANCE VACCINE R&D
5.2.2              RESTRAINTS
5.2.2.1            HIGH COST OF VACCINE DEVELOPMENT
5.2.3              OPPORTUNITIES
5.2.3.1            HIGH GROWTH PROSPECTS IN EMERGING MARKETS
5.2.3.2            FOCUS ON THERAPEUTIC VACCINES
5.2.3.3            USE OF ADJUVANTS IN VACCINES
5.2.4              CHALLENGES
5.2.4.1            INADEQUATE ACCESS TO VACCINES
5.2.5              BURNING ISSUES
5.2.5.1            PRODUCT RECALLS

6.... INDUSTRY INSIGHTS

6.1             REGULATORY LANDSCAPE
6.1.1              NORTH AMERICA
6.1.2              EUROPE
6.1.3              ASIA
6.1.4              ROW
6.2             KEY PIPELINE PRODUCTS
6.3             NEW VACCINE OPPORTUNITIES
6.3.1              HIV
6.3.1.1            HIV VACCINE: PRODUCT PIPELINE
6.3.1.2            HIV VACCINE: PUBLIC-PRIVATE INITIATIVES
6.3.1.3            HIV VACCINE: FUNDING
6.3.2              MALARIA
6.3.2.1            MALARIA VACCINE: PRODUCT PIPELINE
6.3.2.2            MALARIA VACCINE: PUBLIC-PRIVATE INITIATIVES
6.3.3              ZIKA
6.3.3.1            ZIKA VACCINE: PRODUCT PIPELINE
6.3.3.2            ZIKA VACCINE: PUBLIC-PRIVATE INITIATIVES
6.3.3.3            ZIKA VACCINE: FUNDING
6.3.4              EBOLA
6.3.4.1            EBOLA VACCINE: PRODUCT PIPELINE
6.3.4.2            EBOLA VACCINE: PUBLIC-PRIVATE INITIATIVES
6.3.4.3            EBOLA VACCINE: FUNDING
6.3.4.4            EBOLA PROJECTS FUNDED BY EC (2014–2020)

7.... VACCINES MARKET, BY TECHNOLOGY

7.1             INTRODUCTION
7.2             CONJUGATE VACCINES
7.2.1              CONJUGATE VACCINES HOLD THE LARGEST SHARE OF THE MARKET
7.3             INACTIVATED & SUBUNIT VACCINES
7.3.1              EASE OF STORAGE AND TRANSPORTATION HAVE MADE INACTIVATED & SUBUNIT VACCINES POPULAR
7.4             LIVE ATTENUATED VACCINES
7.4.1              ISSUES IN PRESERVING AND MAINTAINING LIVE ATTENUATED VACCINES HAVE SLOWED MARKET GROWTH
7.5             RECOMBINANT VACCINES
7.5.1              LACK OF POST-VACCINATION REACTIONS AND REDUCED NEED FOR BOOSTER DOSES ARE DRIVING R&D ON RECOMBINANT VACCINES
7.6             TOXOID VACCINES
7.6.1              COMPANY INITIATIVES AND THE INTRODUCTION OF NEW VACCINES WILL SUPPORT MARKET GROWTH

8.... VACCINES MARKET, BY TYPE

8.1             INTRODUCTION
8.2             MONOVALENT VACCINES
8.2.1              IN 2018, THE MONOVALENT VACCINES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET
8.3             MULTIVALENT VACCINES
8.3.1              INCREASING INITIATIVES BY COMPANIES TO DEVELOP NEW MULTIVALENT VACCINES ARE DRIVING THE GROWTH OF THIS SEGMENT

9.... VACCINES MARKET, BY DISEASE INDICATION.. 68

9.1             INTRODUCTION
9.2             PNEUMOCOCCAL DISEASE
9.2.1              PNEUMOCOCCAL DISEASE ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET
9.3             INFLUENZA
9.3.1              INFLUENZA VACCINES SEGMENT TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
9.4             DTP
9.4.1              INCREASING ACCESSIBILITY OF DTP VACCINES IN DEVELOPING COUNTRIES TO DRIVE MARKET GROWTH
9.5             HPV
9.5.1              GROWING PREVALENCE OF HPV INFECTIONS TO SUPPORT MARKET GROWTH
9.6             MENINGOCOCCAL DISEASE
9.6.1              RISING INCIDENCE OF MENINGOCOCCAL DISEASE TO SUPPORT THE GROWTH OF THIS MARKET SEGMENT
9.7             HEPATITIS
9.7.1              HIGH PREVALENCE OF HEPATITIS INFECTIONS IS DRIVING THE DEMAND FOR IMMUNIZATION
9.8             POLIO
9.8.1              GOVERNMENT INITIATIVES TO SUPPORT THE GROWTH OF THIS MARKET SEGMENT
9.9             ROTAVIRUS
9.9.1              RISING INCIDENCE OF ROTAVIRUS INFECTIONS TO DRIVE MARKET GROWTH
9.10          MMR
9.10.1            RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA WILL SUPPORT THE GROWTH OF THIS MARKET SEGMENT. 80
9.11          HERPES ZOSTER
9.11.1            HERPES ZOSTER VACCINES TO WITNESS STABLE DEMAND DURING THE FORECAST PERIOD
9.12          VARICELLA
9.12.1            PROMOTION OF IMMUNIZATION PROGRAMS TO DRIVE THE DEMAND FOR VARICELLA VACCINES
9.13          OTHER DISEASE INDICATIONS

10.. VACCINES MARKET, BY ROUTE OF ADMINISTRATION

10.1          INTRODUCTION
10.2          INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION
10.2.1            INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET
10.3          ORAL ADMINISTRATION
10.3.1            POSSIBILITY OF IRRITATION OF THE GASTRIC MUCOSA MAY LIMIT THE GROWTH OF THIS SEGMENT
10.4          OTHER ROUTES OF ADMINISTRATION

11.. VACCINES MARKET, BY PATIENT TYPE

11.1          INTRODUCTION
11.2          PEDIATRIC PATIENTS
11.2.1            IN 2018, THE PEDIATRIC PATIENTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET
11.3          ADULT PATIENTS
11.3.1            THE ADULT PATIENTS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD.. 92

12.. VACCINES MARKET, BY REGION

12.1          INTRODUCTION
12.2          NORTH AMERICA
12.2.1            US
12.2.1.1          THE US IS THE LARGEST MARKET FOR VACCINES
12.2.2            CANADA
12.2.2.1          HIGH INCIDENCE OF INFECTIOUS DISEASES IS DRIVING THE DEMAND FOR VACCINES IN THE COUNTRY
12.3          EUROPE
12.3.1            GERMANY
12.3.1.1          SIGNIFICANT INVESTMENTS IN R&D TO SUPPORT MARKET GROWTH
12.3.2            UK
12.3.2.1          LAUNCH OF NEW PRODUCTS TO SUPPORT MARKET GROWTH IN THE UK IN THE COMING YEARS
12.3.3            FRANCE
12.3.3.1          FAVORABLE GOVERNMENT INITIATIVES FOR IMMUNIZATION TO SUPPORT MARKET GROWTH IN FRANCE
12.3.4            ITALY
12.3.4.1          CONJUGATE VACCINES TO ACCOUNT FOR THE LARGEST SHARE OF THE ITALIAN MARKET
12.3.5            SPAIN
12.3.5.1          RISING INVESTMENTS IN VACCINE DEVELOPMENT BY PRIVATE ORGANIZATIONS TO SUPPORT MARKET GROWTH IN SPAIN
12.3.6            REST OF EUROPE
12.4          ASIA
12.4.1            JAPAN
12.4.1.1          GOVERNMENT INITIATIVES FOR INCREASING THE ACCESSIBILITY OF VACCINES TO DRIVE MARKET GROWTH IN JAPAN
12.4.2            CHINA
12.4.2.1          GROWING INVESTMENTS IN THE BIOTECHNOLOGY SECTOR TO DRIVE MARKET GROWTH IN CHINA
12.4.3            INDIA
12.4.3.1          GROWTH OF THE BIOTECHNOLOGY SECTOR AND DEVELOPMENT OF NEW VACCINES TO SUPPORT MARKET GROWTH IN INDIA
12.4.4            REST OF ASIA
12.5          REST OF THE WORLD
12.5.1            LATIN AMERICA
12.5.2            OTHER ROW COUNTRIES

13.. COMPETITIVE LANDSCAPE

13.1          OVERVIEW
13.2          MARKET SHARE ANALYSIS
13.3          COMPETITIVE LEADERSHIP MAPPING (2018). 126
13.3.1            VISIONARY LEADERS
13.3.2            INNOVATORS
13.3.3            DYNAMIC DIFFERENTIATORS
13.3.4            EMERGING COMPANIES
13.4          COMPETITIVE SITUATION AND TRENDS
13.4.1            AGREEMENTS, CONTRACTS, AND COLLABORATIONS
13.4.2            PRODUCT LAUNCHES & APPROVALS
13.4.3            ACQUISITIONS
13.4.4            EXPANSIONS

14.. COMPANY PROFILES

(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, SWOT ANALYSIS, MNM VIEW)*
14.1          GLAXOSMITHKLINE PLC.
14.2          MERCK & CO., INC.
14.3          PFIZER, INC.
14.4          SANOFI PASTEUR SA
14.5          CSL LIMITED
14.6          EMERGENT BIOSOLUTIONS, INC.
14.7          JOHNSON & JOHNSON
14.8          ASTRAZENECA
14.9          SERUM INSTITUTE OF INDIA PVT., LTD.
14.10        BAVARIAN NORDIC
14.11        MITSUBISHI TANABE PHARMA CORPORATION.. 165
14.12        DAIICHI SANKYO COMPANY, LIMITED
14.13        PANACEA BIOTEC, LTD.
14.14        BIOLOGICAL E
14.15        BHARAT BIOTECH
14.16        OTHER COMPANIES
14.16.1         SINOVAC BIOTECH, LTD.
14.16.2         INCEPTA VACCINE, LTD.
14.16.3         VALNEVA SE
14.16.4         VBI VACCINES INC.
14.16.5         PT BIO FARMA (PERSERO)
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, SWOT ANALYSIS, MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.

15.. APPENDIX

LIST OF TABLES

TABLE 1              INCIDENCE OF INFECTIOUS DISEASES
TABLE 2              NIH FUNDING FOR VACCINE RESEARCH, 2014–2020 (USD MILLION)
TABLE 3              IMMUNIZATION COVERAGE, BY DISEASE, 2016 VS. 2018
TABLE 4              REGULATORY AUTHORITIES IN EUROPE
TABLE 5              REGULATORY AUTHORITIES IN ASIA
TABLE 6              KEY PIPELINE VACCINES
TABLE 7              VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 8              COST OF MENINGOCOCCAL CONJUGATE VACCINES FOR PEDIATRIC PATIENTS
TABLE 9              COST OF MENINGOCOCCAL CONJUGATE VACCINES FOR ADULT PATIENTS
TABLE 10            CONJUGATE VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 11            EXAMPLES OF INACTIVATED & SUBUNIT VACCINES
TABLE 12            INACTIVATED & SUBUNIT VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 13            LIVE ATTENUATED VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 14            EXAMPLES OF RECOMBINANT VACCINES
TABLE 15            RECOMBINANT VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 16            TOXOID VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 17            VACCINES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 18            MONOVALENT VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 19            EXAMPLES OF NOTABLE MULTIVALENT VACCINES AVAILABLE IN THE MARKET
TABLE 20            MULTIVALENT VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 21            VACCINES MARKET, BY DISEASE INDICATION, 2017–2024 (USD MILLION)
TABLE 22            LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL VACCINES IN THE MARKET
TABLE 23            PNEUMOCOCCAL DISEASE VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 24            LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES IN THE MARKET
TABLE 25            INFLUENZA VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 26            LIST OF COMMERCIALLY AVAILABLE DTP VACCINES IN THE MARKET
TABLE 27            DTP VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 28            LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET
TABLE 29            HPV VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 30            LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES IN THE MARKET
TABLE 31            MENINGOCOCCAL DISEASE VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 32            LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES IN THE MARKET
TABLE 33            HEPATITIS VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 34            LIST OF COMMERCIALLY AVAILABLE POLIO VACCINES IN THE MARKET
TABLE 35            POLIO VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 36            LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES IN THE MARKET
TABLE 37            ROTAVIRUS VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 38            LIST OF COMMERCIALLY AVAILABLE MMR VACCINES IN THE MARKET
TABLE 39            MMR VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 40            HERPES ZOSTER VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 41            LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES IN THE MARKET
TABLE 42            VARICELLA VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 43            LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS
TABLE 44            OTHER DISEASE INDICATION VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 45            VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 46            ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION
TABLE 47            VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY REGION, 2017–2024 (USD MILLION)
TABLE 48            VACCINES MARKET FOR ORAL ADMINISTRATION, BY REGION, 2017–2024 (USD MILLION)
TABLE 49            VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2017–2024 (USD MILLION)
TABLE 50            VACCINES MARKET, BY PATIENT TYPE, 2017–2024 (USD MILLION)
TABLE 51            VACCINES MARKET FOR PEDIATRIC PATIENTS, BY REGION, 2017–2024 (USD MILLION)
TABLE 52            NORTH AMERICA: VACCINES MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 53            VACCINES MARKET FOR ADULT PATIENTS, BY REGION, 2017–2024 (USD MILLION)
TABLE 54            NORTH AMERICA: VACCINES MARKET FOR ADULT PATIENTS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 55            VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 56            NORTH AMERICA: VACCINES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 57            NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 58            NORTH AMERICA: VACCINES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 59            NORTH AMERICA: VACCINES MARKET, BY DISEASE INDICATION, 2017–2024 (USD MILLION)
TABLE 60            NORTH AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2017–2024 (USD MILLION)
TABLE 61            NORTH AMERICA: VACCINES MARKET, BY PATIENT TYPE, 2017–2024 (USD MILLION)
TABLE 62            NUMBER OF NEW INFECTIOUS DISEASE CASES IN THE US, 2017
TABLE 63            US: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 64            US: VACCINES MARKET, BY PATIENT TYPE, 2017–2024 (USD MILLION)
TABLE 65            NUMBER OF NEW INFECTIOUS DISEASE CASES IN CANADA, 2015–2017
TABLE 66            CANADA: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 67            CANADA: VACCINES MARKET, BY PATIENT TYPE, 2017–2024 (USD MILLION)
TABLE 68            EUROPE: VACCINES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 69            EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 70            EUROPE: VACCINES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 71            EUROPE: VACCINES MARKET, BY DISEASE INDICATION, 2017–2024 (USD MILLION)
TABLE 72            EUROPE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 73            EUROPE: VACCINES MARKET, BY PATIENT TYPE, 2017–2024 (USD MILLION)
TABLE 74            GERMANY: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 75            UK: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 76            FRANCE: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 77            ITALY: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 78            SPAIN: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 79            ROE: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 80            ASIA: HEALTH EXPENDITURE PER CAPITA, BY COUNTRY, 2000 VS. 2014 VS. 2016 (USD)
TABLE 81            ASIA: VACCINES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 82            ASIA: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 83            ASIA: VACCINES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 84            ASIA: VACCINES MARKET, BY DISEASE INDICATION, 2017–2024 (USD MILLION)
TABLE 85            ASIA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 86            ASIA: VACCINES MARKET, BY PATIENT TYPE, 2017–2024 (USD MILLION)
TABLE 87            DISEASE INCIDENCE IN JAPAN, 2016–2018
TABLE 88            JAPAN: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 89            CHINA: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 90            INDIA: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 91            ROA: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 92            ROW: VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 93            ROW: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 94            ROW: VACCINES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 95            ROW: VACCINES MARKET, BY DISEASE INDICATION, 2017–2024 (USD MILLION)
TABLE 96            ROW: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 97            ROW: VACCINES MARKET, BY PATIENT TYPE, 2017–2024 (USD MILLION)
TABLE 98            LATIN AMERICA: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 99            LATIN AMERICA: VACCINES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 100          LATIN AMERICA: VACCINES MARKET, BY DISEASE INDICATION, 2017–2024 (USD MILLION)
TABLE 101          LATIN AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 102          LATIN AMERICA: VACCINES MARKET, BY PATIENT TYPE, 2017–2024 (USD MILLION)
TABLE 103          OTHER ROW COUNTRIES: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 104          OTHER ROW COUNTRIES: VACCINES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 105          OTHER ROW COUNTRIES: VACCINES MARKET, BY DISEASE INDICATION, 2017–2024 (USD MILLION)
TABLE 106          OTHER ROW COUNTRIES: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 107          OTHER ROW COUNTRIES: VACCINES MARKET, BY PATIENT TYPE, 2017–2024 (USD MILLION)

 

FIGURE 1            VACCINES MARKET SEGMENTATION
FIGURE 2            RESEARCH DESIGN
FIGURE 3            BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 4            BOTTOM-UP APPROACH
FIGURE 5            TOP-DOWN APPROACH
FIGURE 6            DATA TRIANGULATION METHODOLOGY
FIGURE 7            VACCINES MARKET, BY TECHNOLOGY, 2019 VS. 2024 (USD MILLION)
FIGURE 8            VACCINES MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION)
FIGURE 9            VACCINES MARKET, BY DISEASE INDICATION, 2019 VS. 2024 (USD MILLION)
FIGURE 10          VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2019 VS. 2024 (USD MILLION)
FIGURE 11          VACCINES MARKET, BY PATIENT TYPE, 2019 VS. 2024 (USD MILLION)
FIGURE 12          VACCINES MARKET: GEOGRAPHICAL SNAPSHOT
FIGURE 13          HIGH PREVALENCE OF DISEASES AND RISING FOCUS ON IMMUNIZATION PROGRAMS ARE DRIVING MARKET GROWTH
FIGURE 14          CONJUGATE VACCINES ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN VACCINES MARKET IN 2018
FIGURE 15          ASIA TO WITNESS THE HIGHEST GROWTH IN THE VACCINES MARKET
FROM 2019 TO 2024
FIGURE 16          VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 17          REGULATORY APPROVAL PROCESS FOR VACCINES
FIGURE 18          NORTH AMERICA WILL CONTINUE TO DOMINATE THE VACCINES MARKET IN 2024
FIGURE 19          NORTH AMERICA: VACCINES MARKET SNAPSHOT
FIGURE 20          EUROPE: VACCINES MARKET SNAPSHOT
FIGURE 21          ASIA: VACCINES MARKET SNAPSHOT
FIGURE 22          VACCINES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018
FIGURE 23          COMPETITIVE LEADERSHIP MAPPING: VACCINES MARKET (2018)
FIGURE 24          GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT (2018)
FIGURE 25          MERCK & CO., INC.: COMPANY SNAPSHOT (2018)
FIGURE 26          PFIZER, INC.: COMPANY SNAPSHOT (2018)
FIGURE 27          SANOFI PASTEUR SA: COMPANY SNAPSHOT (2018)
FIGURE 28          CSL LIMITED: COMPANY SNAPSHOT (2018)
FIGURE 29          EMERGENT BIOSOLUTIONS, INC.: COMPANY SNAPSHOT (2018)
FIGURE 30          JOHNSON & JOHNSON: COMPANY SNAPSHOT (2018)
FIGURE 31          ASTRAZENECA: COMPANY SNAPSHOT (2018)
FIGURE 32          BAVARIAN NORDIC: COMPANY SNAPSHOT (2018)
FIGURE 33          MITSUBISHI TANABE PHARMA CORPORATION: COMPANY SNAPSHOT (2018)
FIGURE 34          DAIICHI SANKYO COMPANY: COMPANY SNAPSHOT (2018)
FIGURE 35          PANACEA BIOTEC: COMPANY SNAPSHOT (2018)

当レポートのプレスリリースは発行されておりません。